UK Covid cases soar above 40k for 5th day - as rates rise by 23% week-on-week

By Danya Bazaraa

The number of Covid cases in the UK has increased by 44,917 as another 45 fatalities are reported.

It is the fifth day in a row that the number of coronavirus cases has risen by above 40,000.

Last Monday, November 15, a further 39,705 Covid-19 infections were announced, with 47 new deaths.

It was a surge of 23% in a week for the number of cases, although deaths dropped by almost a fifth.

The previous Monday cases increased by 32,322, while fatalities were up by 57.

Today's figures come after The Mirror reported a more infectious strain of Covid-19 which may cause less symptomatic cases is spreading across the UK.

The Delta variant strain AY.4.2 accounted for around 12% of samples gathered in a recent government study, which ran up to November 5.

Members of medical staff wearing PPE (POOL/AFP via Getty Images)

Do you have a story? Email webnews@mirror.co.uk

Cases of the sub-variant were growing at 2.8% a day, meaning it was spreading quickly across the UK.

It is thought to be 10 to 15% more infectious than other Delta variants, paving the way for it to become the dominant strain in the UK in several months.

On a more positive note, early research suggests that it may be less likely to cause symptomatic cases than previous iterations.

A Covid-positive patient on the ICU ward (file photo) (Getty Images)

Pfizer Inc said today its Covid-19 vaccine provided strong long-term protection against the virus in a late-stage study conducted among youngsters aged 12 to 15 years.

A two-dose series of the vaccine was 100% effective against Covid-19, measured seven days through over four months after the second dose, the company said.

The long-term data will support planned submissions for full-regulatory approval of the vaccine in the age group in the United States and worldwide.

A nurse prepares to administer the Covid-19 vaccine (Getty Images)

Pfizer and BioNTech will seek clearance for a 30 micrograms dose of the vaccine for those aged 12 and above.

The vaccine was authorised for emergency use in people aged 12-15 years by the U.S. Food & Drug Administration in May, and granted full approval for use in people aged 16 and above in August.


What is inkl?

Important stories

See news based on value, not advertising potential. Get the latest news from around the world.

Trusted newsrooms

We bring you reliable news from the world’s most experienced journalists in the most trusted newsrooms.

Ad-free reading

Read without interruptions, distractions or intrusions of privacy.